102125-62-2

Basic information

• Product Name: N-ISOPROPYL-4-PIPERIDINECARBOXAMIDE HYDROCHLORIDE
• Synonyms: N-ISOPROPYL-4-PIPERIDINECARBOXAMIDE HYDROCHLORIDE;N-isopropylpiperidine-4-carboxamide hydrochloride;REF DUPL: N-isopropylpiperidine-4-carboxamide hydrochloride;N-isopropylpiperidine-4-carboxamide
• CAS NO: 102125-62-2
• Molecular Formula: C9H19ClN2O
• Molecular Weight: 206.72
• Mol File: 102125-62-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-ISOPROPYL-4-PIPERIDINECARBOXAMIDE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-ISOPROPYL-4-PIPERIDINECARBOXAMIDE HYDROCHLORIDE(102125-62-2)
• EPA Substance Registry System: N-ISOPROPYL-4-PIPERIDINECARBOXAMIDE HYDROCHLORIDE(102125-62-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 102125-62-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
N-Isopropyl-4-piperidinecarboxamide hydrochloride is used as a chemical intermediate for the synthesis of various pharmaceutical compounds, contributing to the development of new drug candidates.
Used in Neurological Disorders Treatment:
N-Isopropyl-4-piperidinecarboxamide hydrochloride is used as a potential therapeutic agent for neurological disorders, leveraging its analgesic and anticonvulsant properties to manage pain and seizures.
Used in Pain Management:
N-Isopropyl-4-piperidinecarboxamide hydrochloride is used as an analgesic, helping to alleviate pain by interacting with pain receptors and pathways in the body.
Used in Epilepsy Treatment:
N-Isopropyl-4-piperidinecarboxamide hydrochloride is used as an anticonvulsant, serving to prevent or reduce the frequency of seizures in individuals with epilepsy.

Upstream product

• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 498-94-2 isonipecotic acid 
• 1016716-09-8 tert-butyl 4-(isopropylcarbamoyl)piperidine-1-carboxylate 
• 280115-99-3 tert-butyl 4-(chlorocarbonyl)-piperidine-1-carboxylate 

Relevant articles and documents

Improving selectivity preserving affinity: New piperidine-4-carboxamide derivatives as effective sigma-1-ligands

We report the design, synthesis and binding evaluation against 1 and 2 receptors of a series of new piperidine-4-carboxamide derivatives variously substituted on the amide nitrogen atom. Specifically, we assessed the effects exerted on receptor affinity by substituting the N-benzylcarboxamide group present on a series of compounds previously synthesized in our laboratory with different cyclic or linear moieties. The synthesized compounds 2a-o were tested to estimate their affinity and selectivity toward 1 and2 receptors. Very high 1 affinity (Ki Combining double low line 3.7 nM) and Ki2/Ki1 selectivity ratio (351) were found for the tetrahydroquinoline derivative 2k, featuring a 4-chlorobenzyl moiety linked to the piperidine nitrogen atom.

SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity. Such conditions include, but not limited to, arthritis, Alzheimer's disease, autoimmune thyroid disorders, cancer, diabetes, leukemia, T-cell prolymphocytic leukemia, lymphoma, myleoproliferation disorders, lupus, multiple myeloma, multiple sclerosis, osteoarthritis, sepsis, psoriatic arthritis, prostate cancer, T-cell autoimmune disease, inflammatory diseases, chronic and acute allograft transplant rejection, bone marrow transplant, stroke, asthma, chronic obstructive pulmonary disease, allergy, bronchitis, viral diseases, or Type I diabetes, complications from diabetes, rheumatoid arthritis, asthma, Crohn's disease, dry eye, uveitis, inflammatory bowel disease, organ transplant rejection, psoriasis and ulcerative colitis. The present disclosure also relates to process for the preparation of such compounds, and to pharmaceutical compositions containing them.